化滞柔肝颗粒在瑞戈非尼靶向治疗湿热蕴结型中晚期肝癌患者中的效果

doi:10.3969/j.issn.1671-7171.2022.04.009

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1181 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the therapeutic effect of Huazhirougan granules on regofinil targeted therapy of middle and advanced liver cancer patients with damp heat accumulation type.【Methods】A total of 110 patients with damp-heat accumulation type mid-advanced liver cancer admitted to the hospital were randomly divided into two groups. The control group was given symptomatic supportive treatment such as liver protection, antiemetic and leukocytes elevation on the basis of targeted therapy of regorafenil, while the observation group was given Huazhirougan granules treatment on the basis of administration in the control group. The Chinese medicine syndrome scores of damp-heat accumulation type (refer to the evaluation guidelines for clinical research of traditional Chinese medicines), ALT and AST levels,serum carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP)before treatment and 3 months after the treatment were recorded and compared between the two groups. The adverse drug reactionsin both groups were compared as well.【Results】Before treatment, there were no statistically significant differences in terms of all parameters between the two groups (P>0.05).After 3 months of treatment, the scores of the Chinese medicine syndrome (TCM) scores of damp-heat accumulation type were decreased in both groups (P<0.05), and those indicators in the observation group was lower than those in the control group (P<0.05).The ALT and AST levels in the control group were increased (P<0.05), while ALT and AST levels in the observation group did not obvious changes,which were lower than the control group (P<0.05). The total remission rate of the observation group was higher than that of the control group (P<0.05). There were no significant difference in CEA levels between the two groups after 3 months of treatment (P>0.05).The levels of AFP were decreased in both groups (P<0.05), however,AFP level in the observation group was lower than that in the control group (P<0.05).There were no statistically significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). 【Conclusion】Huazhirougan granules used for regorafenil targeted treatment of mid-advanced liver cancer patients with damp-heat accumulation type can improve their clinical symptoms, have a protective effect on liver function, regulate tumor marker levels and reduce regorafenil-induced fatigue.

Key words： Liver Neoplasms/DT Antineoplastic Agents/PD ANTINEOPLASTIC DRUGS (TCD)/PD Treatment Outcome

Received: 17 October 2021

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Jun-rong
	ZHANG Kui

Cite this article:

MA Jun-rong,ZHANG Kui. Efficacy of Huazhirougan Granules on Regofinil Targeted Therapy of Middle and Advanced Liver Cancer Patients with Damp Heat Accumulation Type[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(4): 510-513.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.04.009 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I4/510

[1] POPE E D,KIMBROUGH E O,VEMIREDDY L P,et al. Aberrant lipid metabolism as a therapeutic target in liver cancer[J].Expert Opin Ther Targets,2019,23(6):473-483.
[2] 卢燊,王雄文. 基于中国分期的原发性肝癌中医证候演变规律探析[J].中医学报,2018,33(12):24-27.
[3] 王席玲,赵连山,王晓芸. 化滞柔肝颗粒对湿热淤积型非酒精性脂肪肝的治疗效果[J].世界中医药,2018,13(7):127-130.
[4] 黄仲奎,龙莉玲. 慢性肝病与肝癌MSCT及MRI诊断[M].北京:人民卫生出版社,2012:127-131.
[5] 林龙,王雄文. 病、证、症结合辨治原发性肝癌[J].中医学报,2016,31(9):1274-1276.
[6] 丁世斌,司永仁,吴威. 肝癌诊疗影像学图谱[M]. 沈阳市:辽宁科学技术出版社,2015:104-108.
[7] 陆张政. 肝癌的中医辨证论治及临床探讨[J].湖南中医药大学学报,2018,38(1):339.
[8] 桑秀秀,王丽苹,王睿林,等. 180例乙肝相关性肝癌患者的中医体质分布、证侯类型及临床特点分析[J].中国中西医结合杂志,2018,38(12):1425-1429.
[9] 乔丽娟,邵明义. 化瘀方治疗原发性肝癌中医证候分布规律研究[J].中医学报,2019,34(6):1322-1325.
[10] 罗青,魏仁东. 化滞柔肝颗粒联合硫普罗宁治疗非酒精性脂肪肝的临床研究[J].现代药物与临床,2019,34(5):1394-1397.
[11] YANG J G,HE X F,HUANG B,et al. Rule of changes in serum GGT levels and GGT/ALT and AST/ALT ratios in primary hepatic carcinoma patients with different AFP levels [J].Cancer Biomark,2018,21(4):743-746.
[12] 庄鸿莉,张利敏,许诗霖,等. 基于内源性大麻素探讨皂术茵陈方治疗非酒精性脂肪性肝炎的作用机制[J].中国中西医结合杂志,2019,39(11):1355-1358.
[13] 许京淑,向航,谭军,等. 利妥昔单抗联合赤芍治疗乙型病毒性肝炎病毒阳性非霍奇金淋巴瘤的临床研究[J].中国临床药理学杂志,2018,23(15):69-71.
[14] 黎莹,杨冬阳,赖晓嵘,等. 阿帕替尼联合TACE对肝癌患者AFP、VEGF和CEA的影响[J].肝脏,2018,23(5):426-430.
[15] 吕君,朱鹏飞,刘艳民,等. 黄芪多糖通过Wnt/β-catenin信号通路促进肝癌细胞凋亡研究[J].中草药,2018,49(21):210-215.
[16] 朱云,李成,林鑫盛,等. 白术多糖对肝癌细胞增殖及侵袭的抑制作用及其机制[J].南方医科大学学报,2019,39(10):1180-1185.